Onconetix, Inc. (ONCO) Fair Value 2026

ONCO · Biotechnology ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

4.3 /10

32 fundamental signals · 2 models active

Value Trap Risk

WARN (54/100)

Quick Summary — As of 2026-08-28, Onconetix, Inc. (ONCO) trades at $0.61, versus a $2.19 median fair value across its 2 active models — 258.0% above the current price. QOC: 4.3/10. Value Trap Risk: 54/100 (WARN). 2/13 models active.

Key Facts

Ticker
ONCO
Price
$0.61
Quality Score
4.3/10
Value Trap Risk
54/100
Models Active
2/13
Last Updated
Strength: ML-RIV suggests +316.7% upside with 56% confidence
Risk: Value Trap score of 54 suggests caution despite apparent undervaluation

Is Onconetix, Inc. (ONCO) Undervalued or Overvalued in 2026?

According to CirclFi’s 2-model valuation engine, Onconetix, Inc. (ONCO) appears undervalued as of : the median of 2 independent fair value estimates is $2.19, 258.0% above the current price of $0.61. Estimates range from $1.83 to $2.55. ONCO scores 4.3/10 on fundamental quality and 54/100 on value-trap risk.

For context, the median US equity CirclFi rates trades at an implied -23.4% versus its own 13-model consensus, across 3,809 rated companies as of 2026-08-28. ONCO’s +258.0% gap is wider than that market norm, and the Biotechnology sector median is -64.7%. Full market index →

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy Onconetix, Inc. Stock in 2026? →

What Fair Value Does Each Model Give ONCO?

2 Intrinsic Value Models vs. Current Price ($0.61)

Core Models (Unlocked)
Model Fair Value Upside
Intrinsic · High Conviction
 $2.55 +316.7%
Relative · Low Conviction
 $1.83 +199.2%

All Models Active

All 2 models are displayed above.

What Is Onconetix, Inc. (ONCO) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, the weight of evidence tilts decidedly bullish for Onconetix, Inc.. Trading at $0.61 against an estimated intrinsic value of $2.19, 2 of 2 active models flag meaningful upside of +258.0% at the median. The most optimistic model, ML-RIV, places fair value at $2.55 (+316.7%), while Regime Cross — the most conservative — estimates $1.83 (+199.2%). This +117.6% gap reflects genuine analytical uncertainty about Onconetix, Inc.'s intrinsic worth.

What Do the Models Say About ONCO?

2 of 13 models are currently active for ONCO. All 2 active models suggest the stock trades below fair value. Taken together, their median fair value for ONCO is $2.19 — the figure CirclFi publishes as this stock's fair value. See which stocks rank higher →

How Does ONCO Rank in Biotechnology?

Among 625 Biotechnology stocks, ONCO ranks #482 by Quality of Company score. CirclFi's QOC score of 4.3/10 evaluates 32 fundamental signals. A score of 4.3 reflects mixed fundamentals.

See all Most Undervalued Biotechnology Stocks →

As a biotech sector, Onconetix, Inc. operates in a sector where partnership revenue is a critical driver of valuation. Investors evaluating ONCO should weigh these sector-specific dynamics alongside our model-derived fair values.

Is ONCO a Value Trap?

CirclFi's Value Trap algorithm assigns ONCO a score of 54/100 (WARN). This is a warning signal. Additional research into recent 10-Q filings is recommended. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

2 of 13 models are active for Onconetix, Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi 32-factor quality framework, Onconetix, Inc.'s fundamental quality profile registers 4.3/10. This mixed score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.

The gap between the most bullish and bearish model spans +117.6% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every ONCO valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across ONCO's 2 active models, average confidence is 37%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Onconetix, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biotechnology Stocks Should You Also Analyze?

11 related Biotechnology stocks with 13-model coverage

BYSIBeyondSpring Inc.QOC 4.3JBIOJade Biosciences, Inc.QOC 4.3IKTInhibikase Therapeutics, Inc.QOC 4.4ACHVAchieve Life Sciences, Inc.QOC 4.3PHIOPhio Pharmaceuticals Corp.QOC 4.4APVOAptevo Therapeutics Inc.QOC 4.3PBYIPuma Biotechnology, Inc.QOC 8.7MRVIMaravai LifeSciences Holdings, Inc.QOC 5.8TCRTAlaunos Therapeutics, Inc.QOC 5.0EXELExelixis, Inc.QOC 9.6INCYIncyte CorporationQOC 9.5

Read investment analysis: BYSI · JBIO · IKT · ACHV · PHIO · APVO · PBYI · MRVI · TCRT · EXEL · INCY

Which Other Stocks Have a Similar Quality Score to ONCO?

6 companies across all industries closest to ONCO’s Quality of Company score of 4.3/10.

TRNRInteractive Strength Inc.QOC 4.3ILLRTriller Group Inc.QOC 4.3ADGMAdagio Medical Holdings, Inc.QOC 4.3GDSTChi Special Acquisition Corp.QOC 4.3GLTKGlobalTech CorporationQOC 4.3NVDANVIDIA CorporationQOC 10.0

Read investment analysis: TRNR · ILLR · ADGM · GDST · GLTK · NVDA

Where Does ONCO Sit in CirclFi's Biotechnology Rankings?

ONCO is ranked against every other Biotechnology stock CirclFi covers in each of these screens.

See all Biotechnology stocks ranked →

What Else Do Investors Ask About Onconetix, Inc.’s Valuation?

What is Onconetix, Inc.'s intrinsic value in 2026?

CirclFi puts Onconetix, Inc. (ONCO)'s intrinsic value at $2.19 — the median of 2 independent model estimates as of 2026-08-28, ranging from $1.83 to $2.55. The Quality of Company score is 4.3/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is ONCO overvalued or undervalued right now?

At $0.61, 2 of 2 active models suggest ONCO may be undervalued, while 0 indicate potential overvaluation. The median of all 2 fair value estimates is $2.19, 258.0% above the current price of $0.61 — a consensus view that ONCO is undervalued. The assessment depends on which methodology best fits Onconetix, Inc.'s business model in Biotechnology.

What does a Quality of Company score of 4.3 mean for ONCO?

Onconetix, Inc.'s QOC of 4.3/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores below 5 flag potential fundamental weaknesses requiring careful analysis.

How many valuation models does CirclFi run on ONCO?

CirclFi analyzes ONCO with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 2 of 13 are active for this stock. Read the full methodology →

Is ONCO a value trap in 2026?

Onconetix, Inc.'s Value Trap score is 54/100 (WARN). This elevated score suggests the stock may look undervalued but faces deteriorating fundamentals — declining margins, rising debt, or shrinking revenue could make the apparent discount deceptive. Browse our ranked stock lists to compare value-trap scores across industries. Browse stocks by value-trap risk →

Cite this analysis — “According to CirclFi’s 2-model valuation engine, Onconetix, Inc. (ONCO) has a median fair value of $2.19 — 258.0% above the current price of $0.61 — as of 2026-08-28.” Source: circlfi.com/stock/ONCO/ · Methodology
Primary sources for this ONCO valuation
  • Financial statements: Onconetix, Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001782107) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for ONCO as of ; valuations recomputed .